A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2006
12/05/2006	US7144892 Treatment of cardiovascular and related pathologies
12/05/2006	US7144873 Therapy for anticancer agents, blood disorders; dissolving in nonaqueous solvent
12/05/2006	US7144584 S(+) desmethylselegiline and its use to treat narcolepsy
12/05/2006	US7144569 Mutant gliadin protein whose wild-type sequence can be modified by transglutaminase; fusion protein comprising a non-gliadin sequence; kit comprising antibody to interferon- gamma detects recognition by T-cell
12/05/2006	CA2531834C Pharmaceutical compositions comprising pioglitazone and an insulin secretion enhancer
12/05/2006	CA2434386C Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
12/05/2006	CA2396458C Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
12/05/2006	CA2360313C Glucocorticoid receptor modulators
12/05/2006	CA2334711C Medicaments containing bisphosphonic acids and derivatives thereof which are provided for preventing and treating autoimmune diseases and allergies
12/05/2006	CA2179183C Interleukin-1 receptor antagonist decreases severity of acute pancreatitis
11/2006
11/30/2006	WO2006127284A2 Method of purifying apo-2 ligand/trail using crystallisation in the cold
11/30/2006	WO2006127249A1 Method and composition for treating osteoarthritis
11/30/2006	WO2006126706A1 Prophylactic/therapeutic agent for psychotic disorder such as bipolar mood disorder and schizophrenia, screening method for the same, and method for determination of risk for the development of the disease
11/30/2006	WO2006126688A1 Agent for improvement of insulin resistance
11/30/2006	WO2006126673A1 Combined drug for treating diabetes
11/30/2006	WO2006126541A1 Pharmaceutical composition comprising vitamin k
11/30/2006	WO2006126505A1 Stat function inhibitor and application thereof
11/30/2006	WO2006125816A1 Oral pharmaceutical formulation for treating a cox-2 mediated condition
11/30/2006	WO2006125304A1 Pharmaceutical compositions for treating or preventing coronary artery disease
11/30/2006	WO2006109193A3 Selection of highly efficient antigen presenting cells for regulating immunity and uses thereof
11/30/2006	WO2006088650A3 Method of treating eye injury with local administration of a vegf inhibitor
11/30/2006	WO2005105147A3 Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases
11/30/2006	WO2005080384A9 Benzimidazole derivative and use as aii receptor antagonist
11/30/2006	US20060270730 Histone deacetylase inhibitors as immunosuppressants
11/30/2006	US20060270718 e.g. N-(4-{1-Hydroxy-1-[1-(2-methoxyethyl)-1H-pyrrol-2-yl]-ethyl}-phenyl)-N-methyl-benzenesulfonamide; liver X receptor (LXR) agonist; antidiabetic, antiproliferative agent; lipid, metabolic disorders, obesity, diabetes, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia
11/30/2006	US20060270700 Potentiation of antineoplastic agents using sigma-2 ligands
11/30/2006	US20060270699 Stabilization of hypoxia inducible factor (HIF) alpha
11/30/2006	US20060270691 Purine derivatives as purinergic receptor antagonists
11/30/2006	US20060270681 Pyridazine derivatives
11/30/2006	US20060270679 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
11/30/2006	US20060270676 Hydrazono-malonitriles
11/30/2006	US20060270665 Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
11/30/2006	US20060270643 Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells
11/30/2006	US20060270636 Methods for treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compounds
11/30/2006	US20060270615 Compositions suitable for the treatment of damage caused by ischemia/reper-fusion or oxidative stress
11/30/2006	US20060270607 Pharmaceutical combinations
11/30/2006	US20060269996 Human voltage gated sodium channel beta1A subunit and methods of use
11/30/2006	US20060269892 Methods and systems for enabling and stabilizing tooth movement
11/30/2006	US20060269628 Composition for attenuation of pain or wound healing agents in dosage
11/30/2006	US20060269619 Nutrient system for individualized responsive dosing regimens
11/30/2006	US20060269604 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
11/30/2006	US20060269600 Enhancing bioavailability of oral immediate release tablets for low solubility medicants; respiratory inflammatory disorders
11/30/2006	US20060269594 Liposomal antineoplastic drugs and uses thereof
11/30/2006	US20060269565 Administering a polypeptide fused to an Fc, has T-cell proliferation inhibiting activity to treat autoimmune encephalomyelitis
11/30/2006	US20060269555 Tumor necrosis factor (TNF)-related apoptosis-inducing ligands; anticarcinogenic and antiproliferative agents; graft versus host disease, AIDS, neurodegenerative disorders
11/30/2006	US20060269533 New strains of bifidobacterium having the ability to produce glutamine
11/30/2006	US20060269530 RNA interference compositions and methods
11/30/2006	US20060269510 Orlistat compositions
11/30/2006	US20060269504 Use of alkyl resorcinols in the treatment of acne
11/30/2006	US20060269487 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
11/30/2006	US20060269478 Use of protein occlusion for the selective delivery of small molecules to targets
11/30/2006	CA2613434A1 Method and composition for treating osteoarthritis
11/30/2006	CA2610647A1 Novel inhibitors of pyruvate kinase as therapeutic agents for cancer
11/30/2006	CA2609188A1 Apo-2 ligand/trail formulations
11/30/2006	CA2606902A1 Insulin resistance improver
11/29/2006	EP1726952A1 Method of in vivo screening of therapeutic agent for memory/learning dysfunction by schizophrenia
11/29/2006	EP1726313A1 Drug for preventing and treating arteriosclerosis
11/29/2006	EP1726311A2 Migration of hematopoietic stem cells and progenitor cells to the liver
11/29/2006	EP1726307A2 Methods for treating psychosis associated with glucocorticoid related dysfunction
11/29/2006	EP1726301A1 Oral pharmaceutical composition for treating a COX-2 mediated condition
11/29/2006	EP1726300A1 Oral pharmaceutical formulation for the prevention and/or the treatment of cardiovascular and inflammatory diseases
11/29/2006	EP1725275A1 Bone grafting material, comprising a porous carrier and at least one pyrrolindone, a method for its production and an implant
11/29/2006	EP1725257A1 Chicken anemia virus vaccine from cell line
11/29/2006	EP1725245A2 Manganese and iron based compounds for elastogenesis and connective tissue treatment
11/29/2006	EP1725237A2 Methods for treating alcoholism
11/29/2006	EP1725225A1 Ambroxol for treating acute pains
11/29/2006	EP1725222A2 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
11/29/2006	EP1725102A1 Hiv integrase inhibitors
11/29/2006	EP1497656B1 Diagnosis of carcinoma using raig1 polypeptides
11/29/2006	EP1480624B1 Pharmaceutical tablet
11/29/2006	EP1313504B1 Methods and compositions for inhibiting angiogenesis
11/29/2006	EP1259223A4 Protein matrix materials, devices and methods of making and using thereof
11/29/2006	EP1248604B1 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
11/29/2006	EP1220911B1 P-glycoproteins and uses thereof
11/29/2006	EP1206529B1 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-BETA 1,3-N-ACETYLGALACTOSAMINE-ALPHA-R/(GlcNAc to GalNAc) BETA 1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3
11/29/2006	EP1198251B1 Combination of an anti-ep-cam antibody with a chemotherapeutic agent
11/29/2006	EP1196598B1 Dsp-3 dual-specificity phosphatase
11/29/2006	EP1189936B1 Use of eif4e binding agents in therapy
11/29/2006	EP1146866B1 A method for treating patients with acne by administering a cyclic gmp pde inhibitor
11/29/2006	EP1024792B1 Topical antifungal composition
11/29/2006	EP1023049B1 Preparation of a directly mouldable tabletting auxiliary
11/29/2006	EP1012281B1 Human leukocyte calcium activated potassium channel polypeptide
11/29/2006	EP0937251B1 Purification of antigen-specific t cells
11/29/2006	EP0738149B1 1-aminoindan derivatives and compositions thereof
11/29/2006	EP0605501B2 Use of presynaptic neurotoxin for the treatment of cerebral palsy
11/29/2006	CN1871360A Method of detecting regulation effect of synoviolin activity
11/29/2006	CN1871347A Method and kit for detecting proliferative diseases causing sclerosis, preventive and/or remedy for proliferative diseases causing sclerosis and method and kit for identifying substance efficacious in
11/29/2006	CN1871086A 金属胶体溶液 Metal colloidal solution
11/29/2006	CN1871030A Method of inhibiting secretase activity
11/29/2006	CN1871029A Drug containing chymase inhibitor as the active ingredient
11/29/2006	CN1871024A Remedy and therapeutic method for periodontal diseases and pulpal diseases
11/29/2006	CN1871011A Use of BH4 for the treatment of respiratory diseases
11/29/2006	CN1871010A Prophylaxis and/or treatment of portal hypertension
11/29/2006	CN1871000A Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain
11/29/2006	CN1870995A Cancer treatment with epothilones
11/29/2006	CN1870993A Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof
11/29/2006	CN1870978A Spray drying processes for forming solid amorphous dispersions of drugs and polymers
11/29/2006	CN1870977A Medicinal targeted local lipolysis
11/29/2006	CN1870975A Oral microemulsion composition comprising biphenyldimethyldicarboxylate and silybin
11/29/2006	CN1869061A Peptidomimetic protease inhibitors

1 ... 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 ... 1151